Overview

To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor

Status:
NOT_YET_RECRUITING

Trial end date:
2027-11-10

Target enrollment:

Participant gender:

Summary

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.

Phase:

PHASE1

Details

Lead Sponsor:

Atridia Pty Ltd.